Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824096 | 0.83 | HRH4 (0.47) | TDP1LMNAALDH1A1MAPTHPGD | |
| SCHEMBL1820467 | 0.80 | TDP1 (1.00) | TDP1LMNAHTTL3MBTL1ALDH1A1 | |
| SCHEMBL3242008 | 0.79 | LMNA (1.00) | TDP1LMNAHTTL3MBTL1ALDH1A1 | |
| SCHEMBL1822332 | 0.77 | TDP1 (0.74) | TDP1LMNAHTTL3MBTL1ALDH1A1 | |
| SCHEMBL110101 | 0.74 | ALDH1A1 (0.72) | LMNAL3MBTL1ALDH1A1POLBSIRT6 | |
| SCHEMBL6320995 | 0.72 | TDP1 (0.67) | TDP1LMNAHTTL3MBTL1ALDH1A1 | |
| SCHEMBL5466738 | 0.71 | SIRT6 (0.79) | LMNAHTTALDH1A1MAPTPOLB | |
| SCHEMBL11073261 | 0.70 | TDP1 (0.63) | TDP1LMNAHTTL3MBTL1ALDH1A1 | |
| SCHEMBL21625180 | 0.70 | MEN1 (0.48) | L3MBTL1ALDH1A1MAPTSIRT6HPGD | |
| SCHEMBL4039721 | 0.70 | KMT2A (0.65) | LMNAL3MBTL1ALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981876-B1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LTD (GB) | 2011-05-04 | — | — | EP | disclosed |
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| EP-1981876-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007080401-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | SLC28A1, TPMT, ACE | TDP1 377/4885LMNA 4439/4885HTT 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.